Passiflora for anxiety disorder - PubMed (original) (raw)
Review
Passiflora for anxiety disorder
L S Miyasaka et al. Cochrane Database Syst Rev. 2007.
Abstract
Background: Anxiety is a very common mental health problem in the general population and in the primary care setting. Herbal medicines are popularly used worldwide and could be an option for treating anxiety if shown to be effective and safe. Passiflora (passionflower extract) is one of these compounds.
Objectives: To investigate the effectiveness and safety of passiflora for treating any anxiety disorder.
Search strategy: The following sources were used: electronic databases: Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies), Medline and Lilacs; Cross-checking references; contact with authors of included studies and manufacturers of passiflora.
Selection criteria: Relevant randomised and quasi-randomised controlled trials of passiflora using any dose, regime, or method of administration for people with any primary diagnosis of general anxiety disorder, anxiety neurosis, chronic anxiety status or any other mental health disorder in which anxiety is a core symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder). Effectiveness was measured using clinical outcome measures such as Hamilton Anxiety Scale (HAM-A) and other scales for anxiety symptoms.
Data collection and analysis: Two reviewers independently selected the trials found through the search strategy, extracted data, performed the trial quality analyses and entered data. Where any disagreements occured, the third reviewer was consulted. Methodological quality of the trials included in this review was assessed using the criteria described in the Cochrane Handbook. For dichotomous outcomes, relative risk with 95% confidence intervals (CI) were calculated, and for continuous outcomes, weighted mean difference with 95%CI was used.
Main results: Two studies, with a total of 198 participants, were eligible for inclusion in this review. Based on one study, a lack of difference in the efficacy of benzodiazepines and passiflora was indicated. Dropout rates were similar between the two interventions. Although the findings from one study suggested an improvement in job performance in favour of passiflora (post-hoc outcome) and one study showed a lower rate of drowsiness as a side effect with passiflora as compared with mexazolam, neither of these findings reached statistical significance.
Authors' conclusions: RCTs examining the effectiveness of passiflora for anxiety are too few in number to permit any conclusions to be drawn. RCTs with larger samples that compare the effectiveness of passiflora with placebo and other types of medication, including antidepressants, are needed.
Similar articles
- Valerian for anxiety disorders.
Miyasaka LS, Atallah AN, Soares BG. Miyasaka LS, et al. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004515. doi: 10.1002/14651858.CD004515.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054208 Review. - Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults.
Olthuis JV, Watt MC, Bailey K, Hayden JA, Stewart SH. Olthuis JV, et al. Cochrane Database Syst Rev. 2015 Mar 5;(3):CD011565. doi: 10.1002/14651858.CD011565. Cochrane Database Syst Rev. 2015. PMID: 25742186 Updated. Review. - Second-generation antipsychotics for anxiety disorders.
Depping AM, Komossa K, Kissling W, Leucht S. Depping AM, et al. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008120. doi: 10.1002/14651858.CD008120.pub2. Cochrane Database Syst Rev. 2010. PMID: 21154392 Review. - Cognitive behavioural therapy for anxiety disorders in children and adolescents.
James A, Soler A, Weatherall R. James A, et al. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004690. doi: 10.1002/14651858.CD004690.pub2. Cochrane Database Syst Rev. 2005. PMID: 16235374 Updated. Review. - Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders.
Ipser JC, Carey P, Dhansay Y, Fakier N, Seedat S, Stein DJ. Ipser JC, et al. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005473. doi: 10.1002/14651858.CD005473.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054260 Review.
Cited by
- Machine learning-mediated Passiflora caerulea callogenesis optimization.
Jafari M, Daneshvar MH. Jafari M, et al. PLoS One. 2024 Jan 24;19(1):e0292359. doi: 10.1371/journal.pone.0292359. eCollection 2024. PLoS One. 2024. PMID: 38266002 Free PMC article. - Pharmacological Activities of the Genus Passiflora (Passifloraceae): A Patent Review.
Pereira Leal AEB, de Lavor ÉM, de Menezes Barbosa J, de Moura Fontes Araújo MT, Dos Santos Cerqueira Alves C, de Oliveira Júnior RG, de Lima ÁAN, da Silva Almeida JRG. Pereira Leal AEB, et al. Curr Top Med Chem. 2022;22(28):2315-2328. doi: 10.2174/1568026622666220819160923. Curr Top Med Chem. 2022. PMID: 35986522 - Passiflora incarnata in Neuropsychiatric Disorders-A Systematic Review.
Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K. Janda K, et al. Nutrients. 2020 Dec 19;12(12):3894. doi: 10.3390/nu12123894. Nutrients. 2020. PMID: 33352740 Free PMC article. - Self-care for anxiety and depression: a comparison of evidence from Cochrane reviews and practice to inform decision-making and priority-setting.
Pilkington K, Wieland LS. Pilkington K, et al. BMC Complement Med Ther. 2020 Aug 10;20(1):247. doi: 10.1186/s12906-020-03038-8. BMC Complement Med Ther. 2020. PMID: 32778171 Free PMC article. - Herbal Medicinal Products from Passiflora for Anxiety: An Unexploited Potential.
da Fonseca LR, Rodrigues RA, Ramos AS, da Cruz JD, Ferreira JLP, Silva JRA, Amaral ACF. da Fonseca LR, et al. ScientificWorldJournal. 2020 Jul 20;2020:6598434. doi: 10.1155/2020/6598434. eCollection 2020. ScientificWorldJournal. 2020. PMID: 32765195 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical